Given that our study identified CD69 as a putative serum biomarker in meningiomas, it is plausible to think that this may be caused by the increased presence of tumor growth-limiting CD69+ lymphocytes in the circulation of Grade I meningioma patients. This evidence concerns the gene CD69 and neoplasm.